Clinical Trial Update: Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection [NA]

View source ↗

Summary

A clinical trial evaluating the immunosuppressant everolimus for kidney transplant patients with NK-mediated rejection is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant Failure
• Kidney Transplant Rejection

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Kidney Transplant Failure and Rejection | NA | Status: RECRUITING